New CEO Aims to Transform Patient Access to Clinical Trials on the
Cure Forward Platform
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cure Forward, the leading digital platform empowering cancer patients to
identify targeted therapies and clinical trials, today announced the
appointment of Frank Ingari as CEO. This appointment comes at a time of
rapid growth for the company, which began operating its beta website
earlier this year.
Mr. Ingari has served the consumer, healthcare and information
technology industries for the past 35 years. He previously held CEO
appointments at NaviNet, 5-Star Medicare Advantage plan Essence
Healthcare, and Best-in-KLAS Value-Based Care Service Provider Lumeris,
which Ingari co-founded. His leadership capabilities have resulted in
notable successes across numerous high-growth companies.
As CEO of Navinet, Ingari was instrumental in driving strategic growth
for the nation’s leading healthcare technology supplier of
payer-provider collaboration solutions, culminating in a sale to
NantHealth in January 2016.
Previously, under Ingari’s leadership, Essence Health pioneered an
innovative accountable care solution with Lumeris Corporation to deliver
world-class population management tools, clinical informatics, and
information delivery systems to its members and contracted physicians.
“We are pleased to name Frank Ingari as Cure Forward’s CEO. Frank has a
proven track record of driving transformational growth within the
companies he leads,” said Seth Harrison, Chairman of the Board for Cure
Forward and Managing Partner of New York-based Apple Tree Partners.
“Cure Forward moves beyond the ‘one-size-fits-all’ paradigm for cancer
treatment and represents the first real opportunity for patients to
explore new treatment options. We are thrilled to work with Frank and
the Cure Forward team to fundamentally change the way patients access
There are thousands of active clinical studies for cancer patients in
the US today, but searching for the right trial places a significant
burden on patients and their care teams. Data suggest fewer than 85% of
patients are aware of potential trial options, and only 3% enroll in
them. At the same time, advances in molecular science and immunology are
introducing a steady stream of promising, innovative treatments tailored
for individual patient needs.
“Patients facing multiple rounds of chemo or an unusual diagnosis often
feel lost and discouraged. Navigating cancer can be bewildering for
patients and their care teams. Cure Forward helps patients and their
caregivers manage the unfamiliar territory of genomic and proteomic
testing, test reimbursement, and clinical trial discovery. We help
patients to connect with new treatments emerging now as part of the
great wave of innovation stemming from the sequencing of the human
genome fifteen years ago,” said CEO Frank Ingari.
“Our families, our industry, and our country need to prove the efficacy
of these new treatments. I’m honored to lead Cure Forward in our mission
to help patients find their own best path in consultation with their
For more information, please visit www.cureforward.com.
About Cure Forward
Cure Forward is a multi-sided patient activation platform solving
critical business needs for clinical trial recruiters, health care
providers, and diagnostic laboratories. The company enables cancer
patients and their care teams to use scientific data to access precision
medicine and find targeted treatment options. At no cost to consumers,
Cure Forward’s Clinical Trial Exchange (CTX) presents de-identified
patient profiles to trial recruiters at biotech and pharma companies,
clinical trial sites, CROs, and healthcare systems. Cure Forward
launched its beta in 2016 after being incubated and funded by Apple Tree
Partners, New York, NY. The company is based in Cambridge, Massachusetts.